Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma

被引：9
|
作者：
Tuli, Richard [1 ]
Lo, Simon [1 ]
Koo, Jaimie [1 ]
Pishvaian, Michael [2 ]
Bender, R. Joseph [2 ]
Petricoin, Emanuel [2 ]
Brody, Jonathan [2 ]
Nissen, Nicholas [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Perthera, Mclean, VA USA
来源：
JCO PRECISION ONCOLOGY | 2017年 / 1卷
关键词：
D O I：
10.1200/PO.17.00016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1 / 5
页数：5
相关论文
共 50 条
  • [41] Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma
    Rudloff, Udo
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (03) : 345 - 368
  • [42] Clinical Outcomes of Crizotinib Readministration in Patients with Nonsmall Cell Lung Cancer with Anaplastic Lymphoma Kinase Rearrangement: Case Report and Review of Literature
    Parida, Prasant Kumar
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2023,
  • [43] Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
    Guo, Liting
    Zhang, Haijun
    Shao, Weiwei
    Chen, Baoan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5491 - 5497
  • [44] Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung
    Mohamad, N.
    Jayalakshmi, P.
    Rhodes, A.
    Liam, C-K
    Tan, J-L
    Yousoof, S.
    Rajadurai, P.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2017, 74 (04) : 176 - 180
  • [45] Structural and kinetic characterization of crizotinib with wild-type and mutant anaplastic lymphoma kinase
    McTigue, Michele A.
    Timofeevski, Sergei L.
    Liu, Wei
    Deng, Ya-Li
    Marrone, Tami
    Cui, Jean
    Brooun, Alexei
    CANCER RESEARCH, 2011, 71
  • [46] Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
    Lin, Liping
    Huang, Fuxi
    Chen, Fang
    He, Yan
    Hu, Jiazhu
    Cao, Xiaolong
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (08) : 3491 - 3497
  • [47] Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase I1170N-activating mutation
    Harvey, Melissa
    Irwin, Meredith S.
    Armstrong, Linlea
    Seath, Kim
    Young, Sean
    Gershony, Sharon
    Deyell, Rebecca J.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (06)
  • [48] Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
    Bossi, Elisa
    Aroldi, Andrea
    Brioschi, Filippo A.
    Steidl, Carolina
    Baretta, Silvia
    Renso, Rossella
    Verga, Luisa
    Fontana, Diletta
    Sharma, Geeta G.
    Mologni, Luca
    Mussolin, Lara
    Piazza, Rocco
    Gambacorti-Passerini, Carlo
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : E319 - E321
  • [49] Crizotinib in Anaplastic Large-Cell Lymphoma
    Gambacorti-Passerini, Carlo
    Messa, Cristina
    Pogliani, Enrico M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (08): : 775 - 776
  • [50] Lysocardiolipin Acyltransferase 1-Anaplastic Lymphoma Receptor Tyrosine Kinase: A Novel Crizotinib-Sensitive Fusion Gene in Lung Adenocarcinoma
    Bu, Kunpeng
    Lu, Yang
    Liu, Xiaoyan
    Cheng, Chunyan
    Li, Bixun
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : E55 - E57
12345